Current and emerging drugs for idiopathic pulmonary fibrosis

Expert Opinion on Emerging Drugs

Volumn 12, Issue 4, 2007, Pages 627-646

  Gharaee Kermani, Mehrnaz ^a   Hu, Biao ^a   Thannickal, Victor J ^a   Phan, Sem H ^a   Gyetko, Margaret R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Anti inflammatory agents; Antifibrotic agents; Fibrocytes; Idiopathic pulmonary fibrosis; IFN ; Inflammation; Myofibroblasts; N acetylcysteine; Pathogenesis; Pirfenidone; Repair

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ACETYLCYSTEINE; AZATHIOPRINE; BLEOMYCIN; BOSENTAN; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DECORIN; ETANERCEPT; FG 3019; GAMMA1B INTERFERON; GC 1008; HTS 466284; IMATINIB; IMMUNOMODULATING AGENT; LY 364947; PENICILLAMINE; PIRFENIDONE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; SB 525334; SD 208; TETRATHIOMOLYBDIC ACID; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

CLINICAL TRIAL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FIBROSING ALVEOLITIS; FORCED EXPIRATORY VOLUME; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG FUNCTION; LUNG PARENCHYMA; NONHUMAN; RESPIRATORY FAILURE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG INDUSTRY; HUMANS; IMMUNOLOGIC FACTORS; PULMONARY FIBROSIS;

EID: 36549088641     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.4.627     Document Type: Review

References (205)

1. THANNICKAL VJ, FLAHERTY KR, HYZYRCL RC, LYNCH JP III: Emerging drugs for idiopathic pulmonary fibrosis. Expert Opin. Emerging Drugs (2005) 10(4):707-727.
2. AMERICAN THORACIC SOCIETY; EUROPEAN RESPIRATORY SOCIETY INTERNATIONAL MULTIDISCIPLINARY CONSENSUS: Classification of the idiopathic interstitial pneumonias. This joint statement of the American thoracic society (ATS), and the European respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am. J. Respir. Crit. Care Med. (2002) 165(2):277-304. • This statement proposes a new classification system for the idiopathic interstitial pneumonia/IPF based on differences in prognoses and responses to therapy in patients with different histopathologic patterns.
3. VISSCHER DW, MYERS JL: Histologic spectrum of idiopathic interstitial pneumonias. Proc. Am. Thorac. Soc. (2006) 3:322-329.
4. RAGHU G, WEYCKER D, EDELSHERG J, BRADFORD WZ, OSTER G: Incidence and prevalence of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2006) 174(9):810-816.
5. GHARAEE-KERMANI M, PHAN SH: Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. Curr. Pharm. Des. (2005) 11:3943-3971. • A highly comprehensive review regarding molecular mechanisms of IPF based on understanding host responses to injury and its implications on the past, as well as on the ongoing development of treatment for this complex disease condition.
6. ASK K, MARTIN GEM, KOLB M, GAULDIE J: Targeting genes for treatment in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. (2006) 3:389-393.
7. STRIETER RM: Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. Chest (2005) 128:S526-S532.
8. GROSS TG, HUNNINGHAKE GW: Idiopathic pulmonary fibrosis. N. Engl. J. Med. (2001) 345:517-525.
9. GHARAEE-KERMANI M, GYETKO MR, HU B, PHAN SH: New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis: a potential role for stem cells in the lung parenchyma and implications for therapy. Pharm. Res. (2007) 24(5):819-841. •• A comprehensive review about mechanisms of lung fibrosis based on understanding host responses to injury and challenges the role of stem cells in lung injury and fibrosis and its implications for therapy.
10. GHARAEE-KERMANI M, NOZAKI Y, HATANO K, PHAN SH: Lung interlukin-4 gene expression in a murine model of bleomycin-induced pulmonary fibrosis. Cytokine (2001) 5:138-147.
11. GHARAEE-KERMANI M, PHAN SH: Role of cytokines and cytokine therapy in wound healing and fibrotic diseases. Curr. Pharm. Des. (2001) 7:1083-1103.
12. SWIGRIS JJ, BROWN KK: Idiopathic pulmonary fibrosis: a decade of progress. J. Bars. Pneumol (2006) 32:249-260.
13. LAMA VN, PHAN SH: The extrapulmonary origin of fibroblasts. Proc. Am. Thorac. Soc. (2006) 3:373-376.
14. WILLIS BC, DUBOIS RM, BROK Z: Epithelial origin of myofibroblasts during fibrosis in the lung. Proc. Am. Thorac. Soc. (2006) 3:377-382. • This study demonstrated that inappropriate induction of myofibroblasts causes organ fibrosis. Alveolar epithelial cells may serve as an important source of fibroblasts and myofibroblasts.
15. HASHIMOTO N, JIN H, LIU T, CHENSUE SW, PHAN SH: Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. (2004) 113:243-252.
16. DUNSMORE SE, SHAPIRO SD: The bone marrow leaves its scar: new concepts in pulmonary fibrosis. J. Clin. Invest. (2004) 113:180-182.
17. PHILLIPS RJ, BURDICK MD, HONG K et al.: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. (2004) 114:438-446.
18. HINZ B, PHAN SH, THANNICKAL VJ, GALLI A, BOCHATON-PIALLAT ML, GABBIANI G: The myofibroblast one function, multiple origins. Am. J. Pathol. (2007) 170(6):1807-1816.
19. THANNICKAL VJ, FLAHERTY KR, MARTINEZ FJ, LYNCH JP III: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin. Pharmacother. (2004) 5(8):1671-1686.
20. THANNICKAL VJ, TOEWS GB, WHITE ES, LYNCH JP III, MARTINEZ FJ: Mechanisms of pulmonary fibrosis. Annu. Rev. Med. (2004) 55:395-417. • A conceptual framework for biologic mechanisms of tissue fibrosis based on understanding host responses to injury. Histopathologic variability is explained by differences is host intrinsic factors and extrinsic factors that modulate inflammatory and repair responses.
21. SELMAN M: From anti-inflammatory drugs through antifibrotic agents to lung transportation. A long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. Chest (2002) 123(3):759-761.
22. GRIBBIN J, HUBBARD RB, LE JEUNE I, SMITH, CJ, WEST J, TATA IJ: The incidence and mortality of Idiopathic pulmonary fibrosis and sarcoidosis in rhe UK. Thorax (2006) 61:980-985.
23. BJORAKER JA, RYU JH, ADWIN MK et al.: Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (1998) 157:199-203.
24. WELL AU, HOGABOAM CM: Update in diffuse parenchymal lung disease 2006. Am. J. Respir. Crit. Care Med. (2007) 175(7):655-660.
25. MANNINO DM, ETZEL RA, PARRISH RG: Pulmonary fibrosis deaths in the United States, 1979 - 1991. An analysis of multiple-cause mortality data. Am. J. Respir. Crit. Care Med. (1996) 153(5):1548-1552.
26. SCHWARTZ DA, HELMERS RA, GALVIN JR et al.: Determinants of survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (1994) 149(2 Part 1):450-454.
27. WALTER N, HAROLD RH, COLLARAD HR, KING TE Jr: Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. (2006) 3:330-338.
28. LUPPI F, CERRI S, BEGHE B, FABBRI LM, RICHELDI L: Corticosteroids and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir. Med. (2004) 98:1035-1044.
29. ABDELAZIZ MM, SAMMAN SY, WALI SO, HAMAD MM: Trearment idiopathic pulmonary fibrosis: is thete anything new. Respiratory (2005) 10:284-289.
30. DU BOIS RM: Is idiopathic pulmonary fibrosis now treatable? Am. J. Respir. Crit. Care Med. (2005) 171(9):939-940.
31. BOUROS D, ANTONIOU KM: Current and future therapeutic approaches in idiopathic. Eur. Respir. J. (2005) 26:693-702.
32. BHATT N, BARAN CP, ALLEN J, MAGRO C, MARSH CB: Promising pharmacologic innovations in treating pulmonary fibrosis. Curr. Opin. Pharm. (2006) 6:284-292.
33. RAGHU G, DEPASO WJ, CAIN K et al.: Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. (1991) 144(2):291-296.
34. ZISMAN DA, LYNCH JP III, TOEWS GB, KAZEROONI EA, FLINT A, MARTINEZ FJ: Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: a prospective study in patients who failed to respond to corticosteroids. Chest (2000) 117(6):1619-1626.
35. COULTAS DB: Epidemiology of idiopathic pulmonary fibrosis. In: Idiopathic Pulmonary Fibrosis. Lynch JP III (Ed.), Dekker, Inc., New York, USA (2004):1-30.
36. LAMA VN, FLAHERTY KR, TOEWS GB et al.: Prognostic value of desaturation duting a six-minute-walk test in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med. (2003) 168:1084-1090.
37. HALLSTRAND TS, BOITNAO LJ, JOHNSON WC, SPADA CA, HAYES JG, RAGHU G: The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur. Respir. J. (2005) 25:96-103.
38. LEDERER DJ, ACRASOY SM, WILT JS, D'OVIDIO F, SONETT JR, KAWUT SM: Six minute-walk distance predicts waiting list survival in idiopathic pulmonaty fibrosis. Am. J. Respir. Crit. Care Med. (2006) 174:659-664.
39. MAPLEL DW, HUNT WC, UTTON R, BAUMGARTNER KB, SAMET JM, COULTAS DB: Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax (1998) 53:469-476.
40. BARDALES RH, XIE SS, SCHAEFER RF, HSU SM: Apoptosis is a major pathway responsible for the resolution of type II pneumocytes in acute lung injury. Am. J. Pathol. (1996) 149(3):845-852.
41. UHAL BD, JOSHI I, HUGHES WF, RAMOS C, PARDO A, SELMAN M: Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung. Am. J. Physiol. (1998) 275:L1192-L1199.
42. UHAL BD, JOSHI I, TRUE LA et al.: Fibroblast isolated after fibrotic lung injury induce apoptosis of alveolar epithelial cells in vitro. Am. J. Physiol. (1995) 269:L819-L828.
43. SKALLI O, SCHÜRCH W, SEEMAYER T: Myofibroblasts from diverse pathologic settings are heterogeneous in their content of actin isoforms and intermediate filament proteins. Lab. Invest. (1989) 60:275-285.
44. PHAN SH: Role of the myofibroblast in pulmonary fibrosis. Kidney Int. ( 1996) 49(54):S46-S48.
45. SCHISSEl LS, MATTHEW LD: Telomerase, myofibroblasts, and pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. (2006) 34:520-522.
46. GHARAEE-KERMANI M, PHAN SH: Role of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. In: Idiopatic Pulmonary Fibrosis. Lynch JP III (Ed.), Marrcel Dekker, Inc., New York, USA (2004):509-561.
47. WILLIS BC, LIEBLER JM, LUBY-PHELPS K et al.: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-β1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. (2005) 166:1321-1332. • This study demonstrated that TGF-β is able to induce EMT in AECs. This findings support the possibility that EMT may be a source of myofibroblasts in the fibrotic lung.
48. SWIGRIS JJ, KUSCHNER WJ, KELSEY JL, GOULD MK: Idiopathic pulmonary fibrosis: challenges and opportunities for the clinician and investigator. Chest (2005) 127:275-283.
49. IYER SN, HYDE DM, GIRI SN: Anti-inflammatory effect of pirfenidone in rhe bleomycin-hamster model of lung inflammation. Inflammation (2000) 24(5):477-491.
50. OKU H, NAKAZATO H, HORIKAWA T, TSURUTA Y, SUZUKI R: Pirfenidone suppresses TNF-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur. J. Pharmacol. (2002) 446(1-3):167-176.
51. NAKAZATO H, OKU H, YAMANE S, TSURUTA Y, SUZUKI R: A novel anti-fibrotic agent pirfenidone suppresses TNF-α at the translational level. Eur. J. Pharmacol. (2002) 446(1-3):177-185.
52. LURTON JM, TREJO T, NARAYANAN AS: Pirfenidone inhibits the stimulatory effects of profibrotic cytokines of human lung fibroblasts in vitro. Am. J. Respir. Crit. Care Med. (1996) 153:A403.
53. IYER SN, GURUJEYALAKSHMI G, GIRI SN: Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther. (1999) 291(1):367-373.
54. GURUJEYALAKSHMI G, HOLLINGER MA, GIRI SN: Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am. J. Physiol. (1999) 276(2 Part 1):L311-L318.
55. GIRI SN, LEONARD S, SHI X, MARGOLIN SB, VALLYATHAN V: Effects of pirfenidone on the generation of reactive oxygen species in vitro. J. Environ. Pathol. Toxicol. Oncol. (1999) 18(3):169-177.
56. IYER SN, WILD JS, SCHIEDT MJ, HYDE DM, MARGOLIN SB, GIRI SN: Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J. Lab. Clin. Med. (1995) 125(6):779-785.
57. AL-BAYATI MA, XIE Y, MOHR FC, MARGOLIN SB, GIRI SN: Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem. Pharmacol. (2002) 64(3):517-525.
58. TADA S, NAKAMUTA M, ENJOJI M et al.: Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin. Exp. Pharmacol. Physiol. (2001) 28(7):522-527.
59. WALLER JR, MURPHY GJ, METCALFE MS et al.: Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. Transplant. Proc. (2001) 33(7-8):3816- 3818.
60. RAGHU G, JOHNSON WC, LOCKHART D, MAGETO Y: Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am. J. Respir. Crit. Care Med. (1999) 159(4 Part 1):1061-1069.
61. NAGAI S, HAMADA K, SHIGEMATSU M, TANIYAMA M, YAMAUCHI S, IZUMI T: Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. Intern. Med. (2002) 41(12):1118- 1123.
62. GAHL WA, BRANTLY M, TROENDLE J et al.: Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol. Genet. Metab. (2002) 76(3):234-242.
63. AZUMA A, NUKIWA T, TSUBOI E et al.: Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. (2005) 171(9):1040-1047.
64. SIMONE NL, SOULE BL, GERBER L et al.: Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat. Oncol. (2007) 2:19.
65. ANTONIU SA: Pirfenidone for idiopathic pulmonary fibrosis. Expert Opin. Investig. Drugs (2006) 15(7):823-828.
66. ANTONIU SA: Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. Expert Opin. Investig. Drugs (2005) 14(11):1443-14447.
67. BAUER EA, VALLE JK: Colchicine-induced modulation of collagenase in human skin fibroblast-cultures. J. Invest. Dermatol. (1982) 79:398-403.
68. HERBERT CM, LINDBERG KA, JAYASON MI, BAILEY AJ: Biosynthesis and maturation of skin collagen in scleroderma and effect of D-penicillamine. Lancet (1974) 1:187-192.
69. KING TE Jr: Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am. J. Respir. Crit. Care Med. (2005) 172:268-279.
70. SEHGAL SN: Rapamune (RAPA. rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biol. Chem. (1998) 31:335-340.
71. SIMLER NR, HOWELL DCJ, MARSHALL RP et al.: The rapamycin analogue SDZ RAD attenuated bleomycin-induced pulmonaty fibrosis in rats. Eur. Respir. J. (2002) 19:1124-1127.
72. MURPHY KM, OUYANG W, FARRAR JD et al.: Signaling and transcription in T helper development. Annu. Rev. Immunol. (2000) 18:451-494.
73. WYNN TA: Fibrotic disease and the T(H)1/T(H2 paradigm. Nat. Rev. Immunol. (2004) 4(8):583-594.
74. ZIESCHE R, HOFBAUER E, WITTMANN K, PETKOV V, BLOCK LH: A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl. J. Med. (1999) 341(17):1264-1269.
75. OKADA T, SUGIE I, AISAKA K: Effects of γ-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. Lymphokine Cytokine Res. (1993) 12:87-91.
76. BAJWA EK, AYAS NT, SCHULZER M, MAK E, RYU JH, MALHOTRA A: Interferon γ-1b therapy in idiopathic pulmonary fibrosis: a meta analysis. Chest (2005) 128:203-206.
77. 1b did not affect the primary end point of disease-free survival, which led to the progression of other drug trials.
78. DU BOIS RM: Interferon γ-1b for the treatment of idiopathic pulmonary fibrosis. N. Engl. J. Med. (1999) 341:1302-1304.
79. HONORE I, NUNES H, GROUSSARD O et al.: Acute respiratory failure after interferon-γ therapy of end-stage pulmonaty fibrosis. Am. J. Respir. Crit. Care Med. (2003) 167(7):953-957.
80. CHEN ES, GREENLEE BM, WILLS-KARP M, MOLLER DR: Attenuation of lung inflammation and fibrosis in interferon-γ-deficient mice after intratracheal bleomycin. Am. J. Respir. Cell Mol. Biol. (2001) 24(5):545-555. • This study was the first to document the surprising observation that in response to bleomycin-induced lung injury, IFN-γ-deficient mice showed significantly less lung inflammation, weight loss, mortality and lung fibrosis, relative to wild-type control mice.
81. WANG BZ, ZHENG T, ZHU Z et al.: Interferon γ induction of pulmonary emphysema in adult murine lung. J. Exp. Med. (2000) 192(11):1587-1599. •• By using an inducible over-expressing transgenic modeling system to target IFN-γ to the adult murine lung, this study found that IFN-γ causes a phenotype similar to human chronic obstructive pulmonary disease with progressive emphysema, increased lung volumes, and macrophage and neutrophilic inflammation.
82. BOUROS D, ANTNIOU KM, TZOUVELEKIS A, SIAFAKAS NM: Interferon γ-1b for the treatment of idiopathic pulmonary fibrosis. Expert Opin. Biol. Ther. (2006) 6(10):1051-1060.
83. PACANOWSKI MA, AMSDN GW: interferon γ-1b in the treatment of idiopathic pulmonary fibrosis. Ann. Pharmacother. (2005) 39:1678-1686.
84. PIGUET PF: Is "tumor necrosis factor" the major effector of pulmonary fibrosis? Eur. Cytokine Netw. (1990) 1(4):257-258.
85. LUNDBLAD LK, THOMPSON-FIGUEROA J, LECLAIR T et al.: TNF-α over-expression in lung disease: a single cause behind a complex phenotype. Am. J. Respir. Crit. Care Med. (2005) 171:1363-1370.
86. ZHANG K, GHARAEE-KERMANI M, MCGARRY B REMICK D, PHAN SH: TNF-α mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J. Immunol. (1997) 158:954-959.
87. PIGUET PF, COLLART MA, GRAU GE, KAPANCI Y, VASSALLI P: TNF/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J. Exp. Med. (1989) 170(3):655-663.
88. ZHAG Y, LEE TC, GUILLEMIN B, YU MC, ROM WN: Enhanced IL-1β and TNF-α release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis after asbestos exposure. J. Immunol. (1993) 150:4188-4196.
89. PIGUET PF, VESIN C: Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice. Eur. Respir. J. (1994) 7(3):515-518.
90. ORTIZ LA, LASKY J, LUNGARELLA G et al.: Upregulation of the p75 but not the p55 TNF-α receptor mRNA after silica and bleomycin exposure and protection from lung injury in double receptor knockout mice. Am. J. Respir. Cell Mol. Biol. (1999) 20(4):825-833.
91. LIU JY, BRASS DM, HOYLE GW, BRODY AR: TNF-α receptor knockout mice are protected from the fibroproliferative effects of inhaled asbestos fibers. Am. J. Pathol. (1998) 153(6):1839-1847.
92. FUJITA M, SHANNON JM, MORIKAWA O, GAULDIE J, HARA N, MASON RJ: Overexpression of TNF-α diminishes pulmonary fibrosis induced by bleomycin or transforming growth factor-β. Am. J. Respir. Cell Mol. Biol. (2003) 29(6):669-676.
93. LIU JY, BRODY AR: Increased TGF-β1 in the lungs of asbestos-exposed rats and mice: reduced expression in TNF-α receptor knockout mice. J. Environ. Pathol. Toxicol. Oncol. (2001) 20:97-108.
94. FELDMANN M, MAINI RN: Anti-TNF-α therapy of rheumatoid arthritis: what have we learned? Annu. Rev. Immunol. (2001) 19:163-196.
95. NIDEN A, KOSS M, BOYLEN CT, WILCOX A: An open label pilot study to determine the potential efficacy of TNFR: Fc (Enbrel, Etanercept) in the treatment of usual interstitial pneumonitis. Am. J. Respir. Crit. Care Med. (2002) 165(8):A728 (Abstract).
96. GIRI SN: Novel pharmacological approaches to manage interstitial lung fibrosis in the twenty-first century. Annu. Rev. Phamacol. Toxicol. (2003) 43:73-95.
97. TZORTZAKI EG, ANTONIOU KM, AERVOU MI et al.: Effects of antifibrotic agents on TGF-β1, CTGF and IFN-γ expression in patients with idiopathic pulmonary fibrosis. Respir. Med. (2007) 101(8):1821-1829.
98. DUNCAN MR, FRAZIER KS, ABRAMSON S et al.: Connective tissue growth factor mediates transforming growth factor β-induced collagen synthesis: down-regulation by cAMP. FASEB J. (1999) 13(13):1774-1786.
99. LASKY JA, ORTIZ LA, TONTHAT B et al.: Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am. J. Physiol. (1998) 275(2 Part 1):L365-L371.
100. PAN LH, YAMAUCHI K, UZUKI M et al.: Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur. Respir. J. (2001) 17(6):1220-1227.
101. KHALIL N, GREENBER AH: The role of TGF-β in pulmonary fibrosis. In: Clinical Aplications of TGF-β (Volume 157). Bock GR, Marsh J (Eds), Ciba Foundation Symposium, John Willy & Sons, New York, USA (1991):194-211.
102. THANNICKAL VJ, LEE DY, WHITE ES et al.: Myofibroblast differentiation by transforming growth factor-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. (2003) 278(14):12384-12389. •• This study found an important role for matrix-derived signals via the activation of focal adhesion kinase in the stable differentiation and maintenance of the myofibroblast phenotype.
103. SIME PJ, XING Z, GRAHAM FL et al.: Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J. Clin. Invest. (1997) 100(4):768-776.
104. TOMASEK JJ, GABBIANI G, HINZ B, CHAPONNER C, BROWN RA: Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. (2002) 3(5):349-363.
105. 1 is potent inhibitor of myofibroblast apoptosis.
106. HOROWITZ JC, LEE DY, WAGHRAY M et al.: Activation of the pro-survival phosphatidylinositol 3-kinase/AKT pathway by transforming growth factor-β1 in mesenchymal cells is mediated by p38 MAPK-dependent induction of an autocrine growth factor. J. Biol. Chem. (2004) 279(2):1359- 1367.
107. ROY SG, NOZAKI Y, PHAN SH: Regulation of α-smooth muscle actin gene expression in myofibroblast differentiation from rat lung fibroblasts. Int. J. Biochem. Cell Biol. (2001) 33:723-734.
108. HAGIMOTO N, KUWANO K, INOSHIMA I et al.: TGF-β1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J. Immunol. (2002) 168(12):6470-6478.
109. WILLIS BC, LIEBLER JM, LUBY-PHELPS K et al.: Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-{β}1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. (2005) 166(5):1321-1332.
110. JAIN R, SHAUL PW, BOROK Z, WILLIS BC: Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGFβ1. Am. J. Respir. Cell Mol. Biol. (2007) 37:38-47.
111. SELMAN M, RUIZ V, CABRERA S et al.: TIMPs-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. Am. J. Physiol. (2000) 279:L562-L574.
112. KUNUGI S, FUKUDA Y, ISHIZAKI M, YAMANAKA N: Role of MMP-2 in alveolar epithelial cell repair after bleomycin administration in rabbits. Lab. Invest. (2001) 81:1309-1318.
113. MCGUIRE JK, LI Q, PARKS WC: Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am. J. Pathol. (2003) 162:1831-1843.
114. CUTRONEO KR, WHITE SL, PHAN SH, EHRLICH PH: Therapies for bleomycin induced lung fibrosis through regulation of TGF-β1 induced collagen gene expression. J. Cell. Physiol. (2007) 211:585-589.
115. BORDER WA, NOBLE NA: Transforming growth factor β in tissue fibrosis. N. Engl. J. Med. (1994) 331(19):1286-1292.
116. BROEKELMANN TJ, LIMPER AH, COLBY TV, MCDONALD JA: Transforming growth factor β1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc. Natl. Acad. Sci. USA (1991) 88(15):6642-6646.
117. KHALIL N, O'CONNOR RN, UNRUH HW et al.: Increased production and immunohistochemical localization of transforming growth factor-β in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. (1991) 5(2):155-162.
118. ZHANG K, REKHTER MD, GORDON D, PHAN SH: Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am. J. Pathol. (1994) 145(1):114-125.
119. GURUJEYALAKSHMI G, HOLLINGER MA, GIRI SN: Regulation of transforming growth factor-β1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis. Am. J. Respir. Cell Mol. Biol. (1998) 18:334-342.
120. LETTERIO JJ, ROBERTS AB: Transforming growth factor-β1-deficient mice: identification of isomer-specific activities in vivo. J. Leuk. Biol. (1996) 59:769-774.
121. YANG YA, DUKHANINA B, TANG M et al.: Life time exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. (2002) 109:1607-1615.
122. ZHAO J, SHI W, WANG YL et al.: Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am. J. Physiol. Lung Cell Mol. Physiol. (2002) 282(3):L585-L593.
123. GIRI SN, HYDE DM, HOLLINGER MA: Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice. Thorax (1993) 48(10):959-966.
124. WANG Q, WANG Y, HYDE DM et al.: Reduction of bleomycin induced lung fibrosis by transforming growth factor β soluble receptor in hamsters. Thorax (1999) 54(9):805-812.
125. SHIMIZUKAWA M, EBINA M, NARUMI, KIKUCHI T MUNAKATA H, NUKIWA T: Intratracheal gene transfer of decorin reduces subpleural fibroproliferation induced by bleomycin. Am. J. Physiol. Lung Cell Mol. Physiol. (2003) 284(3):L526-L532.
126. SIRIWARDENA D, KHAW PT, KING AJ et al.: Human antitransforming growth factor β(2) monoclonal antibody - a new modulator of wound healing in trabeculectomy: a randomized placebo controlled clinical study. Ophthalmology (2002) 109(3):427-431.
127. ANTONIOU KM, POTAKA A, BOUROS D, SIAFAKAS MN: Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. Pulm. Pharmacol. Ther. (2007) 20(5):453-461.
128. DERYNCK R, ZHANG YE: Smad-dependent and Smad-independent pathways in TGF-β family signaling. Nature (2003) 425(6958):577-584.
129. HU B, TACK DC, LIU T, WU Z, ULLENBRUCH MR, PHAN SH: Role of Smad3 in the regulation of rat telomerase reverses transcriptase by TGFβ. Oncogene (2006) 25:1030-1041. •• This study provides the role of Smad3 in the inhibition of rat telomerase reverse transcriptase (rTERT) gene transcription by TGF-β. This study found that TGF-β induced Smad3 expression and activation had direct and indirect effects on the inhibition of the rTERT gene transcription.
130. ZHAO Y, GEVERD DA: Regulation of Smad3 expression in bleomycin-induced pulmonary fibrosis: a negative feedback loop of TGF-β signaling. Biochem. Biophys. Res. Commun. (2002) 294:319-323.
131. HU B, WU Z, PHAN SH: Smad3 mediates transformiong growth factof-β-induced-α-smooth muscle actin expression. Am. J. Respir. Cell Mol. Biol. (2003) 29:397-404.
132. NAKAO A, FUJII M, MATSUMURA R et al.: Transient gene transfer and expression of Smad 7 prevents bleomycin-induced lung fibrosis in mice. J. Clin. Invest. (1999) 104:5-11.
133. HUANG M, SHARMA S, ZHU LX et al.: IL-7 inhibits fibroblast TGF-β production and signaling in pulmonary fibrosis. J. Clin. Invest. (2002) 109:931-937.
134. SINGH J, LING LE, SAWYER JS, LEE WC, ZHANG F, YINGLING JM: Transforming rhe TGF-β pathway: convergence of distinct lead generation strategies on a novel kinase pharmacophore for TβRI (ALK5). Curr. Opin. Drug Discov. Dev. (2004) 7(4):437-445.
135. SAWYER JS, BEIGHT DW, BRITT KS et al.: Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo [1,2-b] pyrazole inhibitors of the transforming growth factor-β type 1 receptor kinase domain. Bioorg. Med. Chem. Lett. (2004) 14(13):3581-3584.
136. SINGH J, CHUAQUI CE, BORIACK-SJODIN PA et al.: Successful shape-based virtual screening: the discovery of a potent inhibitor of the type 1 TGF-β receptor kinase (TβRI). Bioorg. Med. Chem. Lett. (2003) 13(24):4355-4359.
137. BONNIAUD P, MARGETTS PJ, KOLB M et al.: Progressive transforming growth factor {β}1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am. J. Respir. Crit. Care Med. (2005) 171(8):889-898.
138. GRYGIELKO ET, MARTIN WM, TWEED CW et al.: Inhibition of gene matkers of fibrosis with a novel inhibitor of TGF {β}-type I receptor kinase in puromycin-induced nephritis. J. Pharmacol. Exp. Ther. (2005) 313(3):943-951.
139. CHAUDHARY NI, ROTH GJ, HILBERG F et al.: Inhibition of PDGF, VEGF and FGF signaling attenuates fibrosis. Eur. Respir. J. (2007) 29(5):976-985.
140. HILDEBRAND AM, ROMARIS M, RASMUSSEN LM et al.: Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor β. Biochem. J. (1994) 302:527-534.
141. KOLB M, MARGETTS PJ, GALT T et al.: Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. (2001) 163:770-777.
142. SAVAGE DG, ANTMAN KH: Imatinib mesylate - a new oral targeted therapy. N Engl. J. Med. (2002) 346(9):683-693.
143. DANIELS CE, WILKES MC, EDENS M et al.: Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J. Clin. Invest. (2004) 114(9):1308-1316.
144. DISTLER JH, JUNGEL A, HUBER LC et al.: Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum. (2007) 56(1):9-12.
145. BUCHDUNGER E, OREILLY T, WOOD J: Pharmacology of imatinib (STI571). Eur. J. Cancer (2002) 38(Suppl. 5):S28-S36.
146. MA CX, HOBDAY TJ, JETT JR: Imatinib mesylate-induced interstitial pneumonitis. Mayo Clin. Proc. (2003) 78(12):1578-1579.
147. ISSHIKI I, YAMAGUCHI K, OKAMOTO S: Interstitial pneumonitis during imatinib therapy. Br. J. Haematol. (2004) 125(4):420.
148. RAJDA J, PHATAK PD: Reversible drug-induced interstitial pneumonitis following imatinib mesylate therapy. Am. J. Hematol (2005) 79(1):80-81.
149. YAMASAWA H, SUGIYAMA Y, BANDO M, OHNO S: Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration (2006) 528:Doi:10.1159/000091272.
150. VITTAL R, ZHANG H, HAN MK, MOORE BB, HOROWITZ JC, THANNICKAK VJ: Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment for fibrotic diseases. J. Pharmacol. Exp. Ther. (2007) 321:35-44.
151. PEACOCK AJ, DAWES KE, SHOCK A, GARY AJ, REEVES JT, LAURENT GJ: Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell Mol. Biol. (1992) 7(5):492-499.
152. SHAHAR I, FIREMAN E, TOPILSKY M et al.: Effect of endothelin-1 on α-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int. J. Immunopharmacol. (1999) 21(11):759-775.
153. SHI-WEN X, CHEN Y, DENTON CP et al.: Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide3- kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell (2004) 15(6):2707-2719.
154. XU S, DENTON CP, HOLMES A, DASHWOOD MR, ABRAHAM DJ, BLACK CM: Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. Pharmacol. (1998) 31(Suppl. 1):S360-S363.
155. SHICHIRI M, SEDIVY JM, MARUMO F, HIRATA Y: Endothelin-1 is a potent survival factor for c-Myc-dependent apoptosis. Mol. Endocrinol. (1998) 12(2):172-180.
156. SHI-WEN X, DENTON CP, DASHWOOD MR et al.: Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J. Invest. Dermatol. (2001) 116(3):417-425.
157. WENDEL M, PETZOLD A, KOSLOWSKI R et al.: Localization of endothelin receptors in bleomycin-induced pulmonary fibrosis in the rat. Histochem. Cell Biol. (2004) 122(5):507-517.
158. PARK SH, SALEH D, GIAID A, MICHEL RP: Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am. J. Respir. Crit. Care Med. (1997) 156(2 Part 1):600-608.
159. MUTSAERS SE, MARSHALL RP, GOLDSACK NR, LAURENT GJ, MCANULTY RJ: Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm. Pharmacol. Ther. (1998) 11(2-3):221-225.
160. UGUCCIONI M, PULSATELLI L, GRIGOLO B et al.: Endothelin-1 in idiopathic pulmonary fibrosis. J. Clin. Pathol. (1995) 48(4):330-334.
161. GIAID A, MICHEL RP, STEWART DJ, SHEPPARD M, CORRIN B, HAMID Q: Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet (1993) 341(8860):1550-1554.
162. SALEH D, FURUKAWA K, TSAO MS et al.: Elevated expression of endothelin-1 and endothelin-converting enzyme-1 in idiopathic pulmonary fibrosis: possible involvement of proinflammatory cytokines. Am. J. Respir. Cell Mol. Biol. (1997) 16(2):187-193.
163. SALANI D, TARABOLETTI G, ROSANO L et al.: Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. (2000) 157:1703-1711.
164. FAGAN KA, MCMURTRY IF, RODMAN DM: Role of endothelin-1 in lung disease. Rispir. Res. (2001) 2:90-101.
165. GUNTHER A, ENKE B, MARKART P et al.: safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. Eur. Respir. J. (2007) 29:713-719. • This study investigates the safety and tolerability of an oral administration of bosentan in patients with IPF. It was found that bosentan treatment did not induce clinically relevant gas exchange abnormalities in IPF patients.
166. CANTIN AM, NORTH SL, FELLS GA, HUBBARD RC, CRYSTAL RG: Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J. Clin. Invest. (1987) 79(6):1665-1673.
167. CANTIN AM, HUBBARD RC, CRYSTAL RG: Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am. Rev. Respir. Dis. (1989) 139(2):370-372.
168. BOROK Z, BUHL R, GRIMES GJ et al.: Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet (1991) 338(8761):215-216.
169. MEYER A, BUHL R, MAGNUSSEN H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. (1994) 7(3):431-436.
170. WHITE AC, THANNICKAL VJ, FANBURG BL: Glutathione deficiency in human disease. J. Nutr. Biochem. (1994) 5:218-226.
171. RINALDO J, GOLDSTEIN RH, SNIDER GL: Modification of oxygen toxicity after lung injury by bleomycin in hamsters. Am. Rev. Respir. Dis. (1982) 126(6):1030-1033.
172. NAKASHIMA JM, LEVIN JR, HYDE DM, GIRI SN: Repeated exposures to enzyme-generated oxidants cause alveolitis, epithelial hyperplasia, and fibrosis in hamsters. Am. J. Pathol. (1991) 139(6):1485-1499.
173. MANOURY B, NENAN S, LECLERC O et al.: The absence of reactive oxygen species production protects mice against bleomycin-induced pulmonary fibrosis. Respir. Res. (2005) 6:11 (Doi:10.1186/1465-9921-6-11).
174. SHAHZEIDI S, SARNSTRAND B, JEFFERY PK, MCANULTY RJ, LAURENT GJ: Oral N-acetylcysteine reduces bleomycin-induced collagen deposition in the lungs of mice. Eur. Respir. J. (1991) 4(7):845-852.
175. CRYSTAL RG: Oxidant and respiratory track epithelial injury pathogenesis and strategies for therapeutic intervention. Am. J. Med. (1991) 91:395-445.
176. THANNICKAL VJ, FANBURG BL: Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor β1. J. Biol. Chem. (1995) 270(51):30334-30338. • This study demonstrates the ability of TGF-β1 differentiated myofibroblasts to secrete hydrogen peroxide, a potential mechanism for oxidative stress in advance stages of idiopathic pulmonary fibrosis.
177. THANNICKAL VJ, DAY RM, KLINZ SG, BASTIEN MC, LARIOS JM, FANBURG BL: Ras-dependent and-independent regulation of reactive oxygen species by mitogenic growth factors and TGF-β1. FASEB J. (2000) 14(12):1741-1748.
178. TOMA TP, BHOWMIK A, RAJAKULASINGAM R: Acetylcysteine in pulmonary fibrosis. N. Engl J. Med. (2005) 354(10):1089-1091.
179. RAHMAN I, MACNEE W: Oxidative stress and regulation of glutathione in lung inflammation. Eur. Respir. J. (2000) 16:534-554.
180. BEHR J, MAIER K, DEGENKOLB B, KROMBACH F, VOGELMEIER C: Antioxidative and clinical effects of high-dose N-acervlcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med. (1997) 156(6):1897-1901.
181. DEMEDTS M, BEHR J, BUHL R et al.: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. (2005) 353(2):2229-2242. •• An interesting study report of an antioxidant strategy for the treatment of IPF patients in clinical trial. The Phase III multicenter, randomized, double-blind, placebo-controlled trial, IFIGENIA, was designed to examine the efficacy of NAC in IPF patients. This study found that therapy with NAC, added to prednisone and azathioprine, preserves vital capacity in patients with IPF more effectively than standard therapy alone. Therefore, this regimen may be a rational treatment option for patients with IPF.
182. HOLGATE ST, PETERS-GOLDEN M, PANETTIERI RA, HENDERSON WR Jr: Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol. (2003) 111(1 Suppl.):S18-S34; discussion S34-S36.
183. SHIM YM, ZHU Z, ZHENG T et al.: Role of 5-lipoxygenase in IL-13-induced pulmonary inflammation and remodeling. J. Immunol. (2006) 177(3):1918-1924.
184. WILBORN J, BAILIE M, COFFEY M, BURDICK M, STRIETER R, PERERS-GOLDEN M: Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J. Clin. Invest. (1996) 97(8):1827-1836.
185. BOROK Z, GILLISSEN A, BUHL R et al.: Augmentation of functional prostaglandin E levels on the respiratory epithelial surface by aerosol administration of prostaglandin E. Am. Rev. Respir. Dis. (1991) 144(5):1080-1084.
186. WILBORN J, CROFFORD LJ, BURDICK MD, KUNKEL SL, STRIETER RM, PERERS-GOLDEN M: Cultured lung fibroblasts isolated from patients with idiopathic pulmonaty fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J. Clin. Invest. (1995) 95(4):1861-1868.
187. LAMA V, MOORE BB, CHRISTENSEN P, TOEWS GB, PETERS-GOLDEN M: Prostaglandin E2 synthesis and suppression of fibroblast proliferation by alveolar epithelial cells is cyclooxygenase-2-dependent. Am. J. Respir. Cell Mol. Biol. (2002) 27(6):752-758.
188. KOHYAMA T, ERTL RF, VALENTI V et al.: Prostaglandin E(2) inhibits fibroblast Chemotaxis. Am. J. Physiol. Lung. Cell Mol. Physiol. (2001) 281(5):L1257-L1263.
189. MIO T, LIU XD, ADACHI Y et al.: Human bronchial epithelial cells modulate collagen gel contraction by fibroblasts. Am. J. Physiol. (1998) 274(1 Part 1):L119-L126.
190. KOLODSICK JE, PETERS-GOLDEN M, LARIOS J, TOEWS GB, THANNICKAL VJ, MOORE BB: Prostaglandin E2 inhibits fibroblast to myofibroblast transition via E. prostanoid receptor 2 signaling and cyclic adenosine monophosphate elevation. Am. J. Respir. Cell Mol. Biol. (2003) 29(5):537-544.
191. 2 inhibition of TGF-β1-induced myofibroblast diffetention is smad-independent but involves cell shape and adhesion-dependent signaling. Am. J. Physiol. Lung Cell Mol. Physiol. (2007) (Article in Press). Doi:1152/ajplung.00489.2006.
192. PETERS-GOLDEN M, BAILIE M, MARSHALL T et al.: Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. (2002) 165(2):229-235.
193. FAILLA M, GENOVSE T, MAZZON E et al.: Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir. Res. (2006) 7:137.
194. ROBIN P, MOLLISON KW: Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids. Prostagland. Lipid Mediat. (2007) 83:188-197.
195. KEANE MP: Angiogenesis and pulmonary fibrosis. Feast or famine? Editorial. Am. J. Respir. Crit. Care Med. (2004) 170:207.
196. BREWER GJ: Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp. Biol. Med. (Maywood) (2001) 226(7):665-673.
197. MAMOU F, MAY KS, SCHIPPER MJ et al.: Tetrathiomolybdate blocks bFGF-but not VEGF-induced incipient angiogenesis in vitro. Anticancer Res. (2006) 26(3A):1753-1758.
198. BREWER GJ, ULLENBRUCH MR, DICK, OLIVAREZ L, PHAN SH: Tetrathiomolybdate therapy protects against bleomycin-induced pulmonaty fibrosis in mice. J. Lab. Clin. Med. (2003) 141(3):210-216.
199. BREWER GJ: Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation. J. Cell Mol. Med. (2003) 7(1):11-20.
200. BREWER GJ, DICK R, ULLENBRUCH MR et al.: Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J. Inorg. Biochem. (2004) 98(12):2160-2167.
201. MARTIN EZ FJ: Idiopathic interstitial pneumonias: usual interstitial pneumonia versus non specific interstitial pneumonia. Proc. Am. Throac. Soc. (2006) 3:81-95.
202. http://www.clinicaltrials.gov ClinicalTrials.gov website. (Accessed 27 April 2007).
203. http://www.fibrogen.com FibroGen website. (Accessed 2007).
204. http://www.techtransfer.umich.edu Tech transfer at the University of Michigan. (Accessed 22 August 2003).
205. http://www.clinicaltrials.gov/ct/show/NCT00131274 Gleevec idiopathic pulmonary fibrosis (IPF) study. (Accessed 4 October 2005).